ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children

被引:2
|
作者
Venkatasubramanian, Raja [1 ,2 ]
Fukuda, Tsuyoshi [2 ,3 ]
Niu, Jing [1 ,2 ]
Mizuno, Tomoyuki [2 ]
Chidambaran, Vidya [1 ,3 ]
Vinks, Alexander A. [2 ,3 ]
Sadhasivam, Senthilkumar [1 ,3 ]
机构
[1] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Clin Pharmacol, Cincinnati, OH 45229 USA
[3] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
关键词
ABCC3; ABCB1; morphine; OCT1; pediatrics; pharmacogenetics; population pharmacokinetics; surgical pain; P-GLYCOPROTEIN; GENE POLYMORPHISMS; RECEIVING MORPHINE; HEALTHY-VOLUNTEERS; CANCER PAIN; MORPHINE-6-GLUCURONIDE; PROTEIN-3; GLUCURONIDES; CODEINE; MORPHINE-3-GLUCURONIDE;
D O I
10.2217/PGS.14.99
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: Large interindividual variability in morphine pharmacokinetics could contribute to variability in morphine analgesia and adverse events. Methods: Influence of weight, genetic polymorphisms, race and sex on morphine clearance and metabolite formation from 220 children undergoing outpatient adenotonsillectomy was studied. A nonlinear mixed effects model was developed in NONMEM to describe morphine and morphine glucuronide pharmacokinetics. Results: Children with ABCC3 -211C>T polymorphism C/C genotype had significantly higher levels of morphine-6-glucuronide and morphine-3-glucuronide formation (similar to 40%) than C/T+T/T genotypes (p < 0.05). In this extended cohort similar to our earlier report, OCT1 homozygous genotypes (n = 13, OCT1(star)2-(star)5/(star)2-(star)5) had lower morphine clearance (14%; p = 0.06), and in addition complementing lower metabolite formation (similar to 39%) was observed. ABCB1 3435C>T TT genotype children had lower levels of morphine-3-glucuronide formation though no effect was observed on morphine and morphine-6-glucuronide pharmacokinetics. Conclusion: Our data suggest that besides bodyweight, OCT1 and ABCC3 genotypes play a significant role in the pharmacokinetics of intravenous morphine and its metabolites in children.
引用
收藏
页码:1297 / 1309
页数:13
相关论文
共 50 条
  • [31] Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes
    Lee, CR
    Pieper, JA
    Frye, RF
    Hinderliter, AL
    Blaisdell, JA
    Goldstein, JA
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 58 (12) : 791 - 794
  • [32] The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1 B1 and OATP1 B3
    Misaka, Shingen
    Knop, Jana
    Singer, Katrin
    Hoier, Eva
    Keiser, Markus
    Mueller, Fabian
    Glaeser, Hartmut
    Koenig, Joerg
    Fromm, Martin F.
    MOLECULAR PHARMACEUTICS, 2016, 13 (02) : 512 - 519
  • [33] Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients
    Matthaei, Johannes
    Brockmoeller, Juergen
    Steimer, Werner
    Pischa, Konstanze
    Leucht, Stefan
    Kullmann, Maria
    Jensen, Ole
    Ouethy, Typhaine
    Tzvetkov, Mladen Vassilev
    Rafehi, Muhammad
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [34] The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition
    Jiang, Fen
    Choi, Jong-Yeol
    Lee, Ju-Hyun
    Ryu, Sunae
    Park, Ze-Won
    Lee, Jong-Gu
    Na, Han-Sung
    Lee, Seok-Yong
    Oh, Woo-Yong
    Chung, Myeon-Woo
    Choi, Seung-Eun
    PHARMACOGENOMICS, 2017, 18 (05) : 459 - 469
  • [35] Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis
    Shi, X. -J.
    Geng, F.
    Jiao, Z.
    Cui, X. -Y.
    Qiu, X. -Y.
    Zhong, M. -K.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (05) : 614 - 624
  • [36] Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach
    Guy-Viterbo, Vanessa
    Baudet, Henry
    Elens, Laure
    Haufroid, Vincent
    Lacaille, Florence
    Girard, Muriel
    Debray, Dominique
    Chardot, Christophe
    Reding, Raymond
    Wallemacq, Pierre
    Musuamba, Flora
    PHARMACOGENOMICS, 2014, 15 (09) : 1207 - 1221
  • [37] Effects of Baicalin on Pharmacokinetics of Florfenicol and mRNA Expression of CYP1A2, CYP2C11, CYP3A1, UGT1A1, MDR1, and ABCC2 in Rats
    Li, Si-Cong
    Li, Xu-Ting
    Wang, Bin
    Yang, Rui
    Zhang, Min
    Li, Jin-Liang
    Huang, Wei
    Cao, Liang
    Xiao, Song-Yang
    PHARMACOGNOSY MAGAZINE, 2020, 16 (67) : 1 - 6
  • [38] Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients
    Miura, Masatomo
    Satoh, Shigeru
    Kagaya, Hideaki
    Saito, Mitsuru
    Numakura, Kazuyuki
    Tsuchiya, Norihiko
    Habuchi, Tomonori
    PHARMACOGENOMICS, 2011, 12 (07) : 977 - 984
  • [39] Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers
    Belmonte, Carmen
    Ochoa, Dolores
    Roman, Manuel
    Saiz-Rodriguez, Miriam
    Wojnicz, Aneta
    Isabel Gomez-Sanchez, Clara
    Martin-Vilchez, Samuel
    Abad-Santos, Francisco
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (06) : 596 - 605
  • [40] Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers
    Kim, Kyoung-Ah
    Joo, Hyun-Jin
    Lee, Hae-Mi
    Park, Ji-Young
    PHARMACOGENETICS AND GENOMICS, 2014, 24 (01) : 35 - 42